---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-034182"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2024-08-28T23:59:59+00:00"
generated_at: "2026-05-31T07:16:58.331757+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics' shareholders approve capital stock decrease, elect directors

## Summary
- Shareholders elected Richard Cilento and Robert Hoffman as Class I directors for terms expiring 2027; both received over 47M votes for.
- Capital Decrease Amendment to reduce authorized capital stock approved with ~48.2M for, 11K against; filed Aug 27.
- Clarifying Amendment to eliminate obsolete provisions approved; Amended and Restated Certificate of Incorporation effective Aug 27.
- WithumSmith+Brown ratified as independent auditor for FY2024 with 54.95M for votes.

## SEC filing metadata
- accession: 0001493152-24-034182
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2024-08-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000149315224034182/0001493152-24-034182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000149315224034182/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-034182
- JSON: https://secwatch.observer/filing/0001493152-24-034182.json
- Plain text: https://secwatch.observer/filing/0001493152-24-034182.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.